Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지

A Comparative Coagulopathic Study for Treatment of Vasospasm by Using Low- and High-molecular Weight Hydroxyethyl Starches

  • Hwang, Sung-Ho (Department of Neurosurgery Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine) ;
  • Won, Yu-Sam (Department of Neurosurgery Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine) ;
  • Yu, Jang-Sun (Department of Neurosurgery Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine) ;
  • Yang, Jae-Young (Department of Neurosurgery Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine) ;
  • Choi, Chun-Sik (Department of Neurosurgery Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine)
  • Published : 2007.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : High-molecular-weight hydroxyethyl starch (HES) compromises blood coagulation more than does low-molecular-weight HES. We compared the effects of low- and high-molecular-weight HES for the treatment of vasospasm and investigated the dose relationship with each other. Methods : Retrospectively, in a series of consecutive 102 patients with subarachnoid hemorrhage (SAH), 35 patients developed clinical symptoms of vasospasm of these fourteen patients were treated with low-molecular weight HES for volume expansion while the other 21 received high-molecular-weight HES as continuous intravenous infusion. Prothrombin time (PT), partial thromboplastin time (PIT), fibrinogen level, and platelet count were all measured prior to initiation, during treatment and after termination of therapy for symptomatic vasospasm. The total dose of HES ranged from 5 L to 14 L and median infusion duration was 10 days. Results : A more pronounced PTT prolongation was observed in high-molecular-weight HES group compared with low-molecular-weight HES group. No other coagulation parameters were altered. Dosage (=duration) shows a positive correlation with PTT. Clinically, significant bleeding episodes were noted in four patients who received high-molecular-weight HES. Conclusion : Coagulopathy was developed in direct proportion to molecular weight of starch and dosages. We propose the extreme caution in the administration of HES solution for the vasospasm treatment.

Keywords

References

  1. Baldassarre S, Vincent JL : Coagulopathy induced by Hydroxyethyl starch. Anesth Analg 84: 451-453, 1997 https://doi.org/10.1097/00000539-199702000-00040
  2. Hall ED : Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Eur J Anaesth 13 : 279-289, 1996 https://doi.org/10.1097/00003643-199605000-00006
  3. Jamnicki M, Bombeli T, Seifert B, Zollinger A, Camenzind V, Pasch T, et al : Low-and Medium molecular-weight Hydroxyethyl starches. Anesthesiology 93 : 1231-1237, 2000 https://doi.org/10.1097/00000542-200011000-00016
  4. Kang SD : Prevention and Medical Management of Vasospasm. J Korean Neurosurg Soc 28: 1226-1231, 1999
  5. Kuitunen A, Hynynen M, Salmenpera M: Hydroxyethyl starch as a prime for cardiopulmonary bypass: effects of two different solutions on haemostasis. Acta Anaesthesiol Stand 37: 652-658, 1993 https://doi.org/10.1111/j.1399-6576.1993.tb03783.x
  6. Korosue K, Ishida K, Matsuoka H : Clinical hemodynamic and hemorheological effects of isovolemic hemodilution in acute cerebral infarction. Neurosurgery 23: 148-153, 1988 https://doi.org/10.1227/00006123-198808000-00003
  7. Korttila K, Grohn P, Gordin A : Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 24 : 273-282, 1984 https://doi.org/10.1002/j.1552-4604.1984.tb01833.x
  8. Kroemer H, Haass A, Muller K : Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5. Eur J Clin Pharmacol 31 : 705-710, 1987 https://doi.org/10.1007/BF00541299
  9. Levy ML, Giannotta SL : Cardiac performance indices during hypervolemic therapy for cerebral vasospasm. J Neurosurg 75 : 2731, 1991
  10. Mayberg MR, Batjer HH, Dacey R: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 25: 2315-2328, 1994 https://doi.org/10.1161/01.STR.25.11.2315
  11. Nearman HS, Herman ML: Toxic effects of colloids in the intensive care unit. Crit Care Clin 7: 713-723, 1991 https://doi.org/10.1016/S0749-0704(18)30302-6
  12. Perez-Trepichio AD, Furlan AJ, Little JR : Hydroxyethyl starch 200/0.5 reduces infarct volume after embolic stroke in rats. Stroke 23: 1782-1790, 1992 https://doi.org/10.1161/01.STR.23.12.1782
  13. Sanfelippo MJ, Suberviola PD : Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch. Am J Clin Pathol 43: 391-393, 1987
  14. Stoll M, Treib J, Schenk JF, Windisch F, Haass A, Wenzel E, et al: No coagulation disorders under high-dose volum therapy with lowmolecular-weight hydroxyethyl starch. Haemostasis 27 : 251-258, 1997
  15. Stump DC, Strauss RG, Henriksen RA : Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion: 27-36, 2002
  16. Stump DC, Strauss RG, Henriksen RA, Patersen RE, Saunders R: A randomized, blinded trial comparing the hemostatic effects of pentastach versus hetastarch. Transfusion 25 : 349-354, 1985 https://doi.org/10.1046/j.1537-2995.1985.25485273815.x
  17. Treib J, Haass A, Pindur G : Coagulation disorders caused by Hydroxyethyl starch. Thromb Haemost 78: 974-983, 1997 https://doi.org/10.1055/s-0038-1657671
  18. Trumble ER, Muizelaar JP, Myseros JS : Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg 82 : 44-47, 1995 https://doi.org/10.3171/jns.1995.82.1.0044
  19. Vorstup S, Andersen A, Juhler M : Hemodilution increases cerebral blood flow in acute ischemic stroke. Stroke 20: 884-889, 1989 https://doi.org/10.1161/01.STR.20.7.884
  20. Weir B : Protection of the brain after aneurysmal rupture. Can J Neural Sci 22 : 177-186, 1995 https://doi.org/10.1017/S0317167100039810